首页> 美国卫生研究院文献>Journal of Alternative and Complementary Medicine >Clinical Efficacy of a West African Sorghum bicolor-Based Traditional Herbal Preparation Jobelyn Shows Increased Hemoglobin and CD4+ T-Lymphocyte Counts in HIV-Positive Patients
【2h】

Clinical Efficacy of a West African Sorghum bicolor-Based Traditional Herbal Preparation Jobelyn Shows Increased Hemoglobin and CD4+ T-Lymphocyte Counts in HIV-Positive Patients

机译:西非高粱双色的传统草药制剂Jobelyn的临床疗效显示HIV阳性患者的血红蛋白和CD4 + T淋巴细胞计数增加

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objectives: The purpose of this study was to evaluate a traditional herbal preparation, Jobelyn,® for its effects on anemia and CD4+ T-cell counts in human immunodeficiency virus–positive (HIV+) patients in Nigeria.>Design: An open-label pilot study involving 10 confirmed (HIV+) patients who were not receiving antiretroviral therapy (ARVT) was performed, in which the patients consumed Jobelyn for 8 weeks, at a dose of 500 mg twice daily. The pilot study was followed by a controlled trial involving 51 patients, all confirmed HIV+, where the patients with CD4+ T-cell counts below 350 cells/μL were receiving ARVT. The eight patients with baseline CD4+ T-cell counts above 350 cells/μL received Jobelyn. The remaining patients who all received ARVT were randomized to ARVT alone versus ARVT+Jobelyn for 12 weeks.>Results: Patients receiving ARVT showed a statistically significant improvement in their CD4+ T-cell counts across the 12-week study period (p<0.01). Patients receiving ARVT+Jobelyn showed a faster improvement, reaching a high level of statistical significance compared to baseline already at 6 weeks (p<0.001), and remained highly significant at 12 weeks (p<0.001).>Conclusions: This is the first controlled study conducted to evaluate efficacy of Jobelyn on immune status in HIV+ patients. The data suggest that consumption of Jobelyn contributed to improved hemoglobin levels and increased CD4+ T-cell counts in Nigerian HIV+ patients. Further studies are needed to examine similar effects in other populations, and to elaborate on the underlying mechanisms, specifically, whether the consumption of Jobelyn supported multiple aspects of bone marrow function.
机译:>目标:本研究的目的是评估传统草药制剂Jobelyn®对尼日利亚人类免疫缺陷病毒阳性(HIV +)患者的贫血和CD4 + T细胞计数的影响。 strong>设计:进行了一项开放标签的先导研究,涉及10名未接受抗逆转录病毒疗法(ARVT)的确诊(HIV +)患者,其中患者服用Jobelyn的剂量为500mg两次,共服用8周日常。在该先导研究之后,进行了一项包含51名患者的对照试验,所有患者均已确认HIV +,其中CD4 + T细胞计数低于350细胞/μL的患者正在接受ARVT。基线CD4 + T细胞计数高于350细胞/μL的8例患者接受Jobelyn治疗。其余全部接受了ARVT的患者被随机分为ARVT和ARVT + Jobelyn组,分别进行了12周。>结果:在整个12周的研究中,接受ARVT的患者的CD4 + T细胞计数有统计学上的显着改善周期(p <0.01)。接受ARVT + Jobelyn治疗的患者在第6周时的基线改善速度更快,达到统计学显着水平(p <0.001),在第12周时仍保持显着水平(p <0.001)。>结论:这是第一项评估Jobelyn对HIV +患者免疫状况功效的对照研究。数据表明,食用Jobelyn有助于改善尼日利亚HIV +患者的血红蛋白水平并增加CD4 + T细胞计数。需要进一步的研究来检查在其他人群中的类似作用,并详细阐明其潜在机制,特别是食用Jobelyn是否支持骨髓功能的多个方面。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号